Since a new coronavirus emerged from Wuhan, China late in 2019, some 3.8 million cases and 265,000 deaths have been reported world-wide. Governments are focused on treating patients acutely sick with COVID-19, the disease caused by the new virus SARS-CoV-2, and slowing the spread of the virus. However, a second crisis of long-term disability is
Over the last many months, social media platforms like Twitter, Facebook, and YouTube have been flooded with disinformation about COVID-19. We wanted to make you aware of the problem, equip you with tools for how to recognize and respond to disinformation, and enlist your help keeping our community safe. According to numerous reports, much of this disinformation comes from organized
On April 13, NIH announced two new funding opportunities for ME/CFS research: PAR-20-165, Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed) PAR-20-168, Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed) What is an R01? What is an R21? R01 and R21 are two common types of funding
What: Researchers at Southern Connecticut State University are currently enrolling individuals in a study that will examine an intervention app for people living with ME/CFS. This app monitors daily perceived and expended energy and fatigue levels. Participants will be asked to complete an online survey about their health history, ME/CFS symptomology, as well as current
A year and a half ago in March of 2018, many of the leading U.S. ME/CFS clinicians came together for a summit at the Bateman Horne Center to discuss diagnostic and treatment methods for ME/CFS. There were three major goals for the summit, including to summarize and publish on key diagnostic and treatment methods; distill
Mark and Marcie Zinn are once again conducting assessments and producing elaborate reports to help patients!
Last month, we presented information about the diagnostic criteria, exploring their similarities and differences. Click here to read that article. This week, we’re reporting on a survey we sent to ME-literate researchers and clinicians. We contacted clinicians who treat or have treated people with myalgic encephalomyelitis (ME) as their main patient population, and researchers who study
NINDS Institute director, Dr. Walter Koroshetz, has made it clear that neither he nor the National Institutes of Health (NIH) are ready to take the immediate actions needed to address the crisis of myalgic encephalomyelitis (ME). In response to #MEAction’s recent letter calling on the NIH to ACTION now for ME, Dr. Koroshetz responded with bureaucratic excuses
NINDS director, Dr. Walter Koroshetz, sent the following response to #MEAction’s Oct. 21st letter calling on the NIH to take immediate actions to address the crisis of myalgic encephalomyelitis (ME). We analyze Dr. Koroshetz letter in blue text below to put his statements into context with the reality of what is happening with the ME crisis. JOIN
Bateman Horne center is re-opening applications for the #MEAction Blue Ribbon Clerkship. Please read below, the application has changed. Announcing a clinical clerkship opportunity for first year medical students, med-peds, internal medicine and family practice residents. We are delighted to announce the #MEAction Blue Ribbon fellowship at the Bateman Horne Center (BHC) with
